References
- George R, Ve RS, Vijaya L. Glaucoma in India: estimated burden of disease. J Glaucoma 2010;19:391–397
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262–267
- Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002;47:53–64
- Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268–1279
- Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Opthalmol 2002;120:701–713
- Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocularhypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134
- Husain S, Yates PW, Crosson CE. Latanoprost-induced changes in rat intraocular pressure: direct or indirect. J Ocul Pharmacol Ther 2008;24:367–372
- Collaborative Normal- Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498–505
- Resul B, Stjernschantz J. Overview: Structure-activity relationships of prostaglandin analogues as ocular hypotensive agents. Expert Opin Ther Pat 1993;3:781–795
- Stjernschantz JW. From PGF2a-isopropyl ester to latanoprost: a review of the development of xalatan. IOVS 2001;42:61134–61145
- Morgan PV, Proniuk S, Blanchard J, Noecker RJ. Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma 2001;10:401–405
- Sakai Y, Yasueda S, Ohtori A. Stability of latanoprost in an ophthalmic lipid emulsion using polyvinyl alcohol. Int J Pharm 2005;23:176–179
- Ochiai A, Danjo K. The stabilization mechanism of latanoprost. Int J Pharm 2011;30:23–30
- Kahook MY, Fechtner RD, Katz LJ, Noecker RJ, Ammar DA. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Curr Eye Res 2012;37:101–108
- Johnson TV, Gupta PK, Vudathala DK, Blair IA, Tanna AP. Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use. J Ocul Pharmacol Ther 2011;27:51–59
- Mochizuki H, Itakura H, Takamatsu M, Kiuchi Y. Efficacy of latanoprost when stored at room temperature. Hiroshima J Med Sci 2008;57:69–72
- Singh R, Rehman Z.U. Current trends in forced degradation study for pharmaceutical product development. J Pharm Educ Res 2012;3:54–63
- Mehta J, Patel V, Kshatri N, Vyas N. A versatile LC method for the simultaneous quantification of latanoprost, timolol and benzalkonium chloride and related substances in the presence of their degradation products in ophthalmic solution. Anal Methods 2010;2:1737–1744
- Collins PW, Pappo R, Dajani EZ. Chemistry and synthetic development of misoprostol. Dig Dis Sci 1985;30:114s–117s
- Vemuri N. Preformulation. In: Nema S, Ludwig JD, editors. Pharmaceutical dosage forms in parenteral medications, 3rd ed. New York: Informa Healthcare; 2010. pp. 57--75
- Boquet MP, Wagner DR. Injectable formulations of poorly water soluble drugs. In: Williams RO, Watts AB, Miller DA, editors. Formulating poorly water soluble drugs. AAPS Press Springer; 2012. pp 209–242
- Salomon RG, Lipid research laboratory, Mechanisms of lipid oxidative fragmentation. Available from: www.case.edu/artsci/chem/faculty/salomon/Mechanisms.htm [last accessed 13 Jan 2014]
- Varma R, Winarko J, Kiat-Winarko T, Winarko B. Concentration of latanoprost ophthalmic solution after 4 to 6 weeks’ use in an eye clinic setting. Invest Ophthalmol Vis Sci 2006;47:222–225
- Paolera MD, Kasahara N, Umbelino CC, Walt JG. Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study. BMC Ophthalmol 2008;8(11):1--5